Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lung cancer,head and neck cancer,colorectal cancer,and ovarian cancer receiving multi-cycle chemotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PEG-rhG-CSF | Experimental | patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PEG-rhG-CSF | Drug |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| The occurrence rate of adverse event during at least three consecutive cycles chemotherapy | up to 30 days after the patient study completion | |
| The severity of adverse event during at least three consecutive cycles chemotherapy | up to 30 days after the patient study completion |
| Measure | Description | Time Frame |
|---|---|---|
| the non-occurrence rate of grade IV neutropenia (ANC <0.5 x 10^9/L)during at least three consecutive cycles chemotherapy | through the study completion,an average of 5 months | |
| the duration of grade IV neutropenia(ANC <0.5 x 10^9/L) during at least three consecutive cycles chemotherapy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C423652 | pegylated granulocyte colony-stimulating factor |
| C455861 | pegfilgrastim |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| through the study completion,an average of 5 months |